Personalised medicine markers of anti-EGFR antibody therapy in metastatic colorectal cancer: accelerating clinical translation with collaborative meta-analyses based on individual-participant data

在选择癌症治疗方法时，我们会考虑“生物标志物”，即预测治疗成功的生物癌症特征。我们将与一个国际组织——高级结直肠癌数据库合作，分析个体患者的临床试验数据。我们打算验证用于选择西妥昔单抗或帕尼单抗治疗的生物标志物。癌症基因KRAS、NRAS、PTEN、PIK3CA、EREG和BRAF将被检测。我们的研究将为个性化治疗提供最好的证据。

When selecting cancer therapy we take into account ‘biomarkers’, biological cancer characteristics that predict treatment success. We will work with an international group, the Advanced Colorectal Cancer Database, to analyse individual patient clinical trial data. We intend to validate biomarkers used to select treatment with cetuximab or panitumumab. Cancer genes called KRAS, NRAS, PTEN, PIK3CA, EREG and BRAF will be examined. Our study will provide best evidence for personalised treatment.